Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease

Roney, Celeste A.; Kulkarni, P. V.; Arora, Veera; Antich, Peter P.; Bonte, Frederick J.; Wu, Aimei; Mallikarjuana, N. N.; Manohar, Sanjeev K.; Liang, Hsiang Fa; Kulkarni, Akshay; Sung, Hsing‐Wen; Sairam, M.; Aminabhavi, Tejraj M.

doi:10.1016/j.jconrel.2005.07.024

Cited by 363 publications

(188 citation statements)

References 74 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…Compared with liposomes, polymeric NPs are more stable when in contact with the biological fluids. Also, their polymeric nature permits the attainment of desired properties such as controlled and sustained drug release, allowing drug release at the targeted site over a period of days or even weeks after injection (Garcia-Garcia et al 2005;Roney et al 2005;Nahar et al 2006). Drug release from NPs is mediated by drug desorption, diffusion through the NP matrix, polymer wall degradation of NPs or some combination of these mechanisms (Lockman et al 2002;Misra et al 2003).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Biomaterials for the central nervous system

Zhong

Bellamkonda

2008

J. R. Soc. Interface.

218

163

View full text Add to dashboard Cite

Biomaterials are widely used to help treat neurological disorders and/or improve functional recovery in the central nervous system (CNS). This article reviews the application of biomaterials in (i) shunting systems for hydrocephalus, (ii) cortical neural prosthetics, (iii) drug delivery in the CNS, (iv) hydrogel scaffolds for CNS repair, and (v) neural stem cell encapsulation for neurotrauma. The biological and material requirements for the biomaterials in these applications are discussed. The difficulties that the biomaterials might face in each application and the possible solutions are also reviewed in this article.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Biomaterials for the central nervous system

Zhong

Bellamkonda

2008

J. R. Soc. Interface.

218

163

View full text Add to dashboard Cite

show abstract

“…The use of modifications of gadolinium labeled A␤1-40, such as putrescine conjugation, to increase the BBB permeability have been reported (Kandimalla et al, 2006;Poduslo et al, 2002;Wengenack et al, 2000); however, when we performed putrescine modification of Gd-K6A␤1-30 we could not obtain consistent labeling of amyloid deposits with this ligand (data not shown). Several other modifications of ligands to increase their BBB permeability have been reported such as incorporation of poly-cationic domains and coupling with proteins that are actively transported into the brain (Franc et al, 2003;Roney et al, 2005). We are currently investigating such methods to increase the BBB permeability of our ligand.…”

Section: Discussionmentioning

confidence: 99%

A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice

Sigurdsson

Wadghiri

Mosconi

et al. 2008

Neurobiology of Aging

View full text Add to dashboard Cite

Amyloid plaques are a characteristic feature in Alzheimer's disease (AD). A novel non-toxic contrast agent is presented, Gd-DTPA-K6A␤1-30, which is homologous to A␤, and allows plaque detection in vivo. MRI was performed on AD model mice and controls prior to and following intracarotid injection with Gd-DTPA-K6A␤1-30 in mannitol solution, to transiently open the blood-brain barrier. A gradient echo T2 * -weighted sequence was used to provide 100 m isotropic resolution with imaging times of 115 min. The scans were examined with voxel-based analysis (VBA) using statistical parametric mapping, for un-biased quantitative comparison of ligand-injected mice and controls. The results indicate that: (1) Gd-DTPA-K6A␤1-30 is an effective, non-toxic, ligand for plaque detection when combined with VBA (p ≤ 0.01-0.001), comparing pre and post-ligand injection scans. (2) Large plaques can be detected without the use of a contrast agent and this detection co-localizes with iron deposition. (3) Smaller, earlier plaques require contrast ligand for MRI visualization. Our ligand when combined with VBA may be useful for following therapeutic approaches targeting amyloid in transgenic mouse models.

show abstract

“…Opsonization by plasma proteins in the systemic circulation is an additional impediment to cerebral drug delivery. Polymeric nanoparticles are the promising candidates to deliver drugs beyond the BBB for the scrutiny of the central nervous system [49].…”

Section: Targeted Nanoparticles For Drug Delivery Through the Blood-bmentioning

confidence: 99%

Target Nanoparticles: An Appealing Drug Delivery Platform

Barakat¹,

Taleb²,

Salehi³

2011

J Nanomedic Nanotechnol

View full text Add to dashboard Cite

Over recent years advancement in nanoparticles drug delivery is widely expected to change the landscape of pharmaceutical and biotechnology industries for the foreseeable future. Nanoparticles are solid colloidal matrix-like particles made of polymers or lipids. Generally administered by the intravenous route like liposome's, they have been developed for the targeted delivery of therapeutic or imaging agents. Nanomaterials have emerged as a promising strategy in delivering therapeutic molecules effectively to diseased sites. Furthermore, most nonmaterial surfaces can be decorated with targeting ligands, enhancing their ability to home to diseased tissues through multivalent interactions with tissue-specific receptors. Thus, targeted therapy provides a means to circumvent the toxicities and lack of treatment response of conventional systemic chemotherapy. Targeted liposome's, micelles, carbon nanotubes and dendrimers incorporated with therapeutic molecules have displayed impressive anticancer effects in animal studies, and these nanomaterials are considered to be close to clinical translation due to their biocompatibility. These carriers are designed in such a way that they are independent in the environments and selective at the pharmacological site. In addition, these nanomaterials have the capability to reverse multidrug resistance a major problem in chemotherapy. Finally, tumor-homing nanosystems that amplify tumor homing can also improve the delivery of compounds to tumors, providing imaging and therapeutic options that were previously unavailable.

show abstract

Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease

Cited by 363 publications

References 74 publications

Biomaterials for the central nervous system

Biomaterials for the central nervous system

A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice

Target Nanoparticles: An Appealing Drug Delivery Platform

Contact Info

Product

Resources

About